Featuring a slide presentation and related discussion from Dr John V Heymach, including the following topics:

• Overview of the biology and treatment landscape of HER2-mutant non-small cell lung cancer (NSCLC) (0:00)
• Datasets evaluating trastuzumab deruxtecan for HER2-mutant NSCLC (5:03)
• Clinical data with zongertinib for HER2-mutant NSCLC (6:35)
• Emerging data with sevabertinib for HER2-mutant NSCLC (14:41)
• Other investigational strategies being evaluated for HER2-mutant NSCLC (19:10)
• Summary of the current and future treatment landscape of HER2-mutant NSCLC (21:52)

CME information and select publications

Featuring perspectives from Prof Giuseppe Curigliano and Dr Priyanka Sharma, including the following topics:

• HER2-Positive Breast Cancer (0:00)
• Hormone Receptor-Positive Breast Cancer (18:16)
• Triple-Negative Breast Cancer (1:05:23)

CME information and select publications

Featuring an interview with Dr Priyanka Sharma, including the following topics:

• Endocrine therapy for hormone receptor-positive, HER2-negative high-risk localized breast cancer (0:00)
  • Johnston SR et al. monarchE: Primary overall survival (OS) results of adjuvant abemaciclib + endocrine therapy (ET) for HR+, HER2-, high-risk early breast cancer (EBC). ESMO 2025;Abstract LBA13.
• Durvalumab in combination with neoadjuvant chemotherapy for localized triple-negative breast cancer (TNBC) (3:25)
  • Loibl S et al. Durvalumab in combination with neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC) – Long-term analysis from the GeparNuevo trial. ESMO 2025;Abstract 292MO. 
• Efficacy and safety findings with TROP2-directed antibody-drug conjugates for metastatic TNBC (5:11)
  • Cortés JC et al. Primary results from ASCENT-03: A randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (chemo) in patients (pts) with previously untreated advanced triple-negative breast cancer (TNBC) who are unable to receive PD-(L)1 inhibitors (PD-[L]1i). ESMO 2025;Abstract LBA20. 
  • de Azambuja E et al. Patient-reported outcomes (PROs) with sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in patients (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) in the phase III ASCENT-04/KEYNOTE-D19 study. ESMO 2025;Abstract LBA22. 
  • Dent R et al. First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial. ESMO 2025;Abstract LBA21. 

CME information and select publications

Featuring an interview with Dr Matthew Lunning, including the following topics:

• Reflection on the advances made in chimeric antigen receptor (CAR) T-cell therapy (0:00)
• Overview of the CAR T-cell therapy administration process (4:40)
• Opportunities for referral for CAR T-cell therapy (10:05)
• Selection of a CAR T-cell therapy based on patient characteristics (16:09)
• Sequencing of CAR T-cell therapy for various non-Hodgkin lymphomas (23:23)
• Safety regulations and mitigation strategies for adverse events (30:36)
• Case: A woman in her early 80s with relapsed/refractory (R/R) diffuse large B-cell lymphoma receives lisocabtagene maraleucel (36:16)
• Case: A man in his early 60s with R/R mantle cell lymphoma receives brexucabtagene autoleucel (43:09)
• Case: A man in his early 60s with R/R multiple myeloma receives ciltacabtagene autoleucel (49:09)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Matthew Lunning, including the following topics:

• Overview of available chimeric antigen receptor (CAR) T-cell therapies (0:00)
• Toxicities associated with CAR T-cell therapy (4:03)
• Mitigation strategies for adverse events (22:02)
• Novel strategies for outpatient infusion (26:34)
• Changes to the CAR T-cell therapy safety regulations (30:23)

CME information and select publications

Featuring an interview with Dr Priyanka Sharma, including the following topics:

• Patient-reported outcomes from the SERENA-6 trial of camizestrant with a CDK4/6 inhibitor for patients with HR-positive, HER2-negative advanced breast cancer and ESR1 mutations emerging during first-line endocrine-based therapy (0:00)
  • Mayer E et al. Patient-reported outcomes (PROs) from the SERENA-6 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1m during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC). ESMO 2025;Abstract 486MO.
• Imlunestrant and abemaciclib versus fulvestrant and abemaciclib for ER-positive, HER2-negative advanced breast cancer: An indirect treatment comparison of 3 Phase III trials (3:00)
  • Bidard FC et al. Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): An indirect treatment comparison (ITC) of three phase 3 trials. ESMO 2025;Abstract 496P .
• Giredestrant in the treatment of ER-positive, HER2-negative breast cancer: The Phase III evERA Breast Cancer and EMPRESS trials (5:39)
  • Mayer E et al. Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the phase III evERA BC trial. ESMO 2025;Abstract LBA16.
  • Llombart-Cussac A et al. Preoperative window-of-opportunity study with giredestrant or tamoxifen (tam) in premenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) and Ki67≥10% early breast cancer (EBC): The EMPRESS study. ESMO 2025;Abstract 294MO.
• Capivasertib/fulvestrant as first- and second-line endocrine-based therapy for PIK3CA/AKT1/PTEN-altered HR-positive advanced breast cancer in the CAPItello-291 trial and gedatolisib/fulvestrant with or without palbociclib for HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer in the VIKTORIA-1 trial.(10:25)
  • Rugo HS et al. Capivasertib plus fulvestrant as first and second-line endocrine-based therapy in PIK3CA/AKT1/PTEN-altered hormone receptor-positive advanced breast cancer: Subgroup analysis from the phase 3 CAPItello-291 trial. ESMO 2025;Abstract 526P.
  • Hurvitz SA et al. Gedatolisib (geda) + fulvestrant ± palbociclib (palbo) vs fulvestrant in patients (pts) with HR+/ HER2-/PIK3CA wild-type (WT) advanced breast cancer (ABC): First results from VIKTORIA-1. ESMO 2025;Abstract LBA17.

CME information and select publications

Featuring perspectives from Dr Komal Jhaveri and Dr Virginia Kaklamani, including the following topics:

• Introduction: Oral Selective Estrogen Receptor Degraders (SERDs) for the General Medical Oncologist (0:00)
• SERD Monotherapy (13:34)
• SERD and CDK Inhibitor Combination — The EMBER-3 Study (35:58)
• SERDs for "Molecular Progression" — The SERENA-6 Study (41:25)

CME information and select publications

Featuring an interview with Dr Priyanka Sharma, including the following topics:

• T-DXd versus trastuzumab emtansine for high-risk HER2-positive primary breast cancer with residual invasive disease after neoadjuvant therapy: Interim analysis of the DESTINY-Breast05 trial (0:00)
  • Geyer C et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05. ESMO 2025;Abstract LBA1. 
• DESTINY-Breast11 trial: Neoadjuvant T-DXd alone or followed by paclitaxel/trastuzumab/pertuzumab for high-risk HER2-positive localized breast cancer (5:42)
  • Harbeck N et al. DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC). ESMO 2025;Abstract 291O. 
• Trastuzumab deruxtecan (T-DXd) and pertuzumab versus a taxane, trastuzumab and pertuzumab for HER2-positive advanced or metastatic breast cancer: Additional analyses of the DESTINY-Breast09 trial (10:00)
  • Loibl S et al. Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): Additional analyses of DESTINY-Breast09 in key subgroups of interest. ESMO 2025;Abstract LBA18. 

CME information and select publications